BMEA Projected Dividend Yield
Biomea Fusion Inc ( NASDAQ : BMEA )Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. Co. has built its proprietary FUSION™ System discovery platform to develop a pipeline of covalent small molecule product candidates. Co.'s product candidate, BMF-219, is designed to be an orally bioavailable, selective irreversible covalent inhibitor of menin, a scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. 20 YEAR PERFORMANCE RESULTS |
BMEA Dividend History Detail BMEA Dividend News BMEA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |